FBR_OC1_37 - Novel CART targeting glycans for Cancer Immunotherapy

Bilateral initiative facts

Promoter:
Instituto de Patologia e Imunologia Molecular da Universidade do Porto(PT)
Bilateral initiative number:
PT-BI020
Initial cost:
€9,561
Initiative Types:
Publication
Study
Study tour
Partners:
Radium Hospital. The group of Dr. Sébastien Walchli.(NO)
Programme:
Programme areas:

Description

Immunotherapy is a treatment which relies on exploiting the patient''s immune system to destroy cancer. One of the most efficient strategies is called Adoptive Cell Transfer (ACT). Upon recognition of these markers, the cytotoxic effector cells get activated and kill the tumours. However, long-term observation suggests that CD19CAR therapy is not optimal and relapse will occur. CAR directed against solid tumours have been less impressive, mainly due to the lack of specific targets urging the quest to find alternative markers. The Radium hospital possesses a collection of hybridoma, including a

Information on the projects funded by the EEA and Norway Grants is provided by the Programme and Fund Operators in the Beneficiary States, who are responsible for the completeness and accuracy of this information.